Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Study probes how lungs handle salt in rare bronchial condition

NCT ID NCT02586883

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how the lungs move chloride, sodium, and bicarbonate in 42 patients with idiopathic bronchiectasis (widened airways of unknown cause). Researchers measured electrical signals in the airway lining during bronchoscopy and took nasal and bronchial samples. The goal was to identify specific transport abnormalities that might explain the condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

42 people

The number who actually took part.

Started

Mar 2016

Finished

Nov 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 to 20 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Common criteria for all patients * Age between 2 and 20 years. * Patient weighing more than 12kg * Patients with a scheduled bronchoscopy under clinical monitoring (assessment of bronchial involvement, local samples for bacteriological and histological examination) * Signature of consent by the patient or by the / the holder (s) of parental authority and the investigator * Patient affiliated to a social security scheme or entitled * Patient with contraception (for woman of childbearing age) Specific criteria for idiopathic bronchiectasis patients Patient with idiopathic bronchiectasis in at least two lobes, diagnosis made after extensive screening of known acquired or congenital causes Specific criteria for "control" patients without abnormal ion transport * Patient Not having bronchiectasis s or any supposed alteration in transepithelial ion transport * Patients with fiberoptic bronchoscopy performed for one of the following indications: * Pulmonary malformations * Laryngeal, tracheal, bronchomalacia * Airway compression * Interstitial pathology * Suspicion of foreign body * Suspected tuberculosis Specific criteria for patients with a typical form of cystic f ibrosis (CF) Patient carrying 2 causing mutations in the CFTR gene (according to CFTR2 database; http://www.cftr2.org/mutations\_history.php) and sweat test\> 60 milliequivalent per liter (mEq/L). Exclusion Criteria: Common criteria for all patients * Smoking passive or active * Not essential bronchial endoscopy in the clinical follow * Extension of bronchoscopy time attributed to the difference in potential bronchial incompatible with the patient's general status * Patient pregnant or breast feeding * Hypersensitivity or cons known contraindications to health products for measurement of DDP (isoproterenol, Amiloride, ATP) Specific criteria for idiopathic DDB patients Presence of other congenital or acquired etiologies of DDB: * Typical or atypical cystic fibrosis, * Immunodeficiency, * Primary ciliary dyskinesia, * Abnormal bronchial wall structure (Williams-Campbell syndrome, Mounier-Kuhn, Ehlers-Danlos syndrome, Marfan's disease) * Infectious DDBs post * Extrinsic or endobronchial obstruction (foreign body, malformation, middle lobe syndrome) * Chronic inhalation (GERD, swallowing disorders, gastroesophageal tracheal fistula) * Allergic bronchopulmonary aspergillosis, * System disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cystic fibrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Necker-Enfants Malades Hospital

    Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.